| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff2f32edc579ac7cec781aa03ae2fc4b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4245 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate |
2020-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2347b17ed95ad46c795ff446e2ce3926
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c3084d2d0679f054116cc93826d1b46 |
| publicationDate |
2020-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020230113-A1 |
| titleOfInvention |
Sphingosine pathway modulating compounds for the treatment of cancers |
| abstract |
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod. |
| priorityDate |
2017-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |